論文・技術情報追加のお知らせ

1. A retrospective analysis of gastrointestinal adverse events associated with nicorandil using the FDA Adverse Event Reporting System (FAERS) following STROBE guidelines.

ニコランジルによる消化器系副作用リスクをFAERSに基づき解析。

対象DB：FAERS

2. Comparative adverse event reporting patterns of desogestrel versus norethisterone in third-generation combined oral contraceptives: A disproportionality analysis of the FAERS satabase.

デソゲストレルとノレチステロンの副作用をFAERSで比較解析。

対象DB：FAERS

3. Biomedical Large Language Models and Prompt Engineering for Causality Assessment of Individual Case Safety Reports in Pharmacovigilance.

生物医学LLMとプロンプト技術を用いた副作用個別因果関係評価。

対象DB：FAERS,VAERS

4. Exploratory research on drugs after lung surgery based on real-world data from the FDA adverse event reporting system database.

FAERSデータを用い、肺手術後の薬剤使用実態を探索的に解析。

対象DB：FAERS

5. The safety profile of lenalidomide, dexamethasone, daratumumab, and bortezomib combinations in multiple myeloma: a retrospective analysis of the FAERS database.

多発性骨髄腫におけるレナリドミド等併用療法の安全性を比較。

対象DB：FAERS

6. Hypotensive Events Associated With PDE-5 Inhibitors in Pulmonary Arterial Hypertension: Assessment of the USFDA Adverse Event Reporting System Using Disproportionality and Interaction Analysis.

肺動脈性高血圧症へのPDE-5阻害薬による低血圧リスクを解析。

対象DB：FAERS

7. Drug-Induced Noninfectious Myocarditis/Pericarditis: A Real-World Pharmacovigilance Study Using the FAERS Database.

薬剤性非感染性心筋炎・心膜炎の主原因薬をFAERSで解析。

対象DB：FAERS

8. Antibiotic use and immune-related adverse events in patients treated with immune checkpoint inhibitors: analysis of the FAERS database.

抗菌薬使用が免疫チェックポイント阻害薬の副作用に与える影響。

対象DB：FAERS

9. Characterization of Safety Signals for Spinal Muscular Atrophy Treatments in Children Aged 0 to 3 Years Potential Safety Patterns for Further Investigation.

0?3歳の小児における脊髄性筋萎縮症治療薬の安全シグナル解析。

対象DB：FAERS

10. Sex-specific risk profiles of drug-associated joint stiffness and deformity: a FAERS-based pharmacovigilance study with Canadian Vigilance Adverse Reaction Database validation.

薬剤性関節硬直・変形のリスクプロファイルの性差をFAERSで解析。

対象DB：FAERS

11. Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.

抗アンドロゲン薬に関連する間質性肺疾患リスクをFAERSで解析。

対象DB：FAERS

12. Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System.

薬剤性ネフローゼ症候群のリアルワールドでの特徴を包括解析。

対象DB：FAERS

13. Post-marketing safety concerns with foscarbidopa/foslevodopa: A pharmacovigilance study with disproportionality analysis based on FAERS.

ホスカルビドパ・ホスレボドパの市販後安全性を不均衡解析。

対象DB：FAERS

14. Hematological toxicities in bevacizumab associated with ovarian cancer: A pharmacovigilance study using FDA adverse event reporting system database.

卵巣癌でのベバシズマブによる血液毒性リスクを不均衡解析。

対象DB：FAERS

15. Immunomodulatory therapies and emerging drug associations with microscopic colitis: A global pharmacovigilance analysis.

免疫調節療法に伴う顕微鏡的大腸炎の新規発生シグナルを解析。

対象DB：FAERS

16. Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS.

免疫チェックポイント阻害薬に関連する副作用の臨床スペクトラム。

対象DB：FAERS

17. Hypothesis-Generating Analysis of Four Immunosuppressive Regimens After Simultaneous Pancreas-Kidney Transplantation Using the United States Food and Drug Administration Adverse Event Reporting System.

膵腎同時移植後の免疫抑制療法4レジメンの安全性をFAERSで評価。

対象DB：FAERS

18. Pharmacovigilance Analysis of Vonoprazan: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System Database.

カリウム競合型アシッドブロッカー・ボノプラザンの副作用解析。

対象DB：FAERS

19. Hyperacusis-inducing drug candidates.

聴覚過敏を誘発する可能性のある薬剤候補を副作用報告から特定。

対象DB：FAERS

20. Exploring GPT-based models for depression detection in adolescents using naturalistic speech: A proof-of-concept study.

自然発話データとGPTモデルを用いた青少年のうつ病検出の試み。

対象DB：JADER

21. [Reactive arthritis after treatment with immune checkpoint inhibitors: A case report].

免疫チェックポイント阻害薬投与後に反応性関節炎を発症した症例。

対象DB：VigiBase

22. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.

GLP-1受容体作動薬に関連する感覚異常（皮膚灼熱感）の解析。

対象DB：FPVD,VigiBase

23. Age-Dependent Cardiovascular Adverse Event Reporting With Pathway-Directed Anticancer Therapies in Children and Adults: A VigiBase Disproportionality Analysis.

小児と成人の分子標的抗がん剤による心血管副作用の年齢差解析。

対象DB：VigiBase

24. Short-term outcomes of self-expanding metallic stents and transanal colorectal tubes as a bridge to surgery for obstructive colon cancer: a nationwide retrospective study.

閉塞性大腸癌へのステントと経肛門チューブの短期成績の比較。

対象DB：DPC

25. Accounting for unmet need in equitable healthcare resource allocation: Synopsis.

医療資源の公平な配分における未充足ニーズの影響に関する解説。

対象DB：CPRD

26. Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.

妊婦の自己免疫疾患と妊娠不良転帰のリスクを英国コホートで調査。

対象DB：CPRD

27. Bowel cancer care in individuals with an intellectual disability: a population-based cohort study of symptoms, diagnostic pathways, treatment and survival.

知的障害者における大腸がんケアの実態（症状・生存率等）を調査。

対象DB：CPRD

28. Clustering of multimorbidity in stroke and transient ischaemic attack survivors: a population-based study.

脳卒中および一過性脳虚血発作生存者における多疾患併存の分類。

対象DB：CPRD

29. Accelerated deficit accumulation in frailty and associations with adverse outcomes: a longitudinal population data analysis.

フレイルにおける健康欠損の急激な蓄積と不良転帰の関連を解析。

対象DB：CPRD

30. Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

フランスの一般医による経口キノロン系抗菌薬の適応外不適切使用。

対象DB：THIN

31. Adherence to LAMA/LABA therapies in middle-aged patients with chronic obstructive pulmonary disease: A group-based trajectory analysis.

中高年COPD患者におけるLAMA/LABA治療の継続パターン解析。

対象DB：DeSC

32. Effect of a financial incentive scheme on promoting prescription of biosimilars: a interrupted time-series analyses.

日本のバイオシミラー処方促進を目的とした報酬加算制度の影響。

対象DB：DeSC